New drug duo aims to outsmart tough lung cancers
NCT ID NCT02638090
Summary
This study is testing whether combining two existing cancer drugs, pembrolizumab and vorinostat, is safe and more effective at controlling advanced non-small cell lung cancer than using pembrolizumab alone. It involves about 120 adults whose cancer has progressed after at least one prior treatment. The research aims to find the best dose and see if the combination helps keep the cancer from growing for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.